-+ 0.00%
-+ 0.00%
-+ 0.00%

NORTHSTRIVE BIOSCIENCES ANNOUNCES POSITIVE FDA RESPONSE SUPPORTING A SUBMISSION OF IND FOR A PHASE 2 CLINICAL TRIAL FOR EL-22 IN COMBINATION WITH GLP-1 RECEPTOR AGONIST FOR OBESITY TREATMENT

Reuters·04/24/2025 12:00:57

Please log in to view news